This company listing is no longer active
Annexin Pharmaceuticals Management
Management criteria checks 1/4
Annexin Pharmaceuticals' CEO is Anders Haegerstrand, appointed in Oct 2019, has a tenure of 4.67 years. directly owns 0.28% of the company’s shares, worth SEK445.22K. The average tenure of the management team and the board of directors is 3.2 years and 0.9 years respectively.
Key information
Anders Haegerstrand
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.7yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.2yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO
Anders Haegerstrand (63 yo)
4.7yrs
Tenure
Dr. Anders Haegerstrand, M.D. Ph.D. is Chief Executive Officer at Annexin Pharmaceuticals AB (publ) since October 2019. He served as Director at Annexin Pharmaceuticals AB since 2018 until 2020. He served...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 4.7yrs | no data | 0.28% SEK 445.2k | |
| Chief Financial Officer | 1.2yrs | no data | no data | |
| Chief Operating Officer | 6.4yrs | no data | 0.055% SEK 85.7k | |
| Chief Scientific & Medical Officer | 8.4yrs | no data | no data | |
| Head of CMC | 3.2yrs | no data | no data | |
| Therapeutic Area Head of Ophthalmology | 2.3yrs | no data | no data | |
| Head of Oncology of Therapy Area | 1.4yrs | no data | no data |
3.2yrs
Average Tenure
52.5yo
Average Age
Experienced Management: ANNX BTA's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of the Board | less than a year | no data | no data | |
| Independent Director | 7.4yrs | no data | 0.18% SEK 289.3k | |
| Director | less than a year | no data | 25.89% SEK 40.6m | |
| Independent Director | 1.4yrs | no data | no data |
0.9yrs
Average Tenure
73yo
Average Age
Experienced Board: ANNX BTA's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/15 15:39 |
| End of Day Share Price | 2024/06/14 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Annexin Pharmaceuticals AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fredrik Thor | Redeye |